Assessment of stanniocalcin-1 as a prognostic marker in human esophageal             squamous cell carcinoma.
Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed             in various types of human malignancies. Although evidence points to the role of             STC1 in human cancers, the clinical significance of STC1 expression in esophageal             cancer has not been well established. Quantitative reverse transcriptase-polymerase             chain reaction and immunohistochemistry were performed to assess the expression             of STC1 in the cancer cell line TE8 and esophageal cancer tissues from 229 esophageal             squamous cell carcinomas (ESCC). Surgically-resected tissue sections were immunostained             for potential regulators of STC1 expression, hypoxia-inducible factor-1α (HIF-1α)             and p53. Marked increase in STC1 mRNA and protein expression was noted in TE8             cells cultured under hypoxic conditions. Overexpression of STC1 mRNA was noted             in ESCC tumors compared to normal counterparts. Positive immunohistochemical staining             for STC1 protein was observed in 38.9% of patients, and correlated significantly             with advanced pT status (p=0.019), poor prognosis [overall survival (p<0.0006)             and disease-free survival (p<0.0002) of ESCC patients who had undergone curative             surgery]. Positive staining for HIF-1α and p53 proteins in ESCC did not correlate             with STC1 expression. The results showed marked induction of STC1 expression under             hypoxia in cultured cells and in esophageal cancer cells and that overexpression             of STC1 was an independent prognostic factor in patients with esophageal cancer             who had undergone curative surgery. STC1 is a potentially useful biomarker for             ESCC treatment.
Department of Gastroenterological Surgery, Graduate School of                     Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Mitsuhiro
M
Shirakawa
Yoshiyuki
Y
Fujiwara
Yurika
Y
Sugita
Jeong-Ho
JH
Moon
Shuji
S
Takiguchi
Kiyokazu
K
Nakajima
Hiroshi
H
Miyata
Makoto
M
Yamasaki
Masaki
M
Mori
Yuichiro
Y
Doki
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D006023:Glycoproteins; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D012333:RNA, Messenger; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C051795:teleocalcin